JP2011517676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011517676A5 JP2011517676A5 JP2011502065A JP2011502065A JP2011517676A5 JP 2011517676 A5 JP2011517676 A5 JP 2011517676A5 JP 2011502065 A JP2011502065 A JP 2011502065A JP 2011502065 A JP2011502065 A JP 2011502065A JP 2011517676 A5 JP2011517676 A5 JP 2011517676A5
- Authority
- JP
- Japan
- Prior art keywords
- flip
- tissue
- nucleotides
- pharmaceutical composition
- double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 210000001519 tissues Anatomy 0.000 claims 20
- 239000002773 nucleotide Substances 0.000 claims 14
- 229920000272 Oligonucleotide Polymers 0.000 claims 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 6
- 230000000295 complement Effects 0.000 claims 5
- 239000000468 intravenous fat emulsion Substances 0.000 claims 5
- 229940107161 Cholesterol Drugs 0.000 claims 4
- 210000004072 Lung Anatomy 0.000 claims 4
- 210000003205 Muscles Anatomy 0.000 claims 4
- 235000012000 cholesterol Nutrition 0.000 claims 4
- 235000011187 glycerol Nutrition 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102000018616 Apolipoproteins B Human genes 0.000 claims 3
- 108010027006 Apolipoproteins B Proteins 0.000 claims 3
- 101700020165 RHOA Proteins 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 101700065091 rho1 Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 230000000692 anti-sense Effects 0.000 claims 2
- 239000008344 egg yolk phospholipid Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 102000019989 lipid binding proteins Human genes 0.000 claims 2
- 108091015473 lipid binding proteins Proteins 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 235000012424 soybean oil Nutrition 0.000 claims 2
- 239000003549 soybean oil Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 claims 1
- 206010049460 Abasia Diseases 0.000 claims 1
- 108020004461 Double-Stranded RNA Proteins 0.000 claims 1
- ONKSSDKXDIVIHK-UHFFFAOYSA-N N,N-didecyldodecanamide Chemical group CCCCCCCCCCCC(=O)N(CCCCCCCCCC)CCCCCCCCCC ONKSSDKXDIVIHK-UHFFFAOYSA-N 0.000 claims 1
- 229920000972 Sense strand Polymers 0.000 claims 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000001921 locked nucleotide group Chemical group 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
Claims (32)
- (a) 脂溶性物質に抱合されている2本鎖オリゴヌクレオチドと、
(b)前記脂溶性物質に抱合された2本鎖オリゴヌクレオチドが 会合されている20%静脈内脂肪エマルションと、
を含む製剤脂質粒子(FLiP)。 - 前記2本鎖オリゴヌクレオチドが、相互に相補的である少なくとも2本の鎖を含む2本鎖RNA(dsRNA)であって、前記2本の鎖のうちの各々が、少なくとも15ヌクレオチドの長さであって、センス鎖が、第1の配列を含み、アンチセンス鎖が、標的遺伝子のうちの少なくとも一部に 相補的である相補性領域を含む第2の配列を含み、前記相補性領域が、30ヌクレオチドの長さより短いものである、請求項1に記載のFLiP。
- 前記dsRNAの少なくとも1つの ヌクレオチドが修飾ヌクレオチドである、請求項2に記載のFLiP。
- 前記修飾ヌクレオチド が、2’−O−メチル修飾ヌクレオチド、5’−ホスホロチオエート基を含むヌクレオチド、およびコレステリル誘導体またはドデカン酸ビスデシルアミド基に結合される末端ヌクレオチドから成る群から選択される、請求項3に記載のFLiP。
- 前記修飾ヌクレオチドが、2’−デオキシ−2’−フルオロ修飾ヌクレオチド、2’−デオキシ−修飾ヌクレオチド、ロックされたヌクレオチド、脱塩基ヌクレオチド、2’−アミノ−修飾ヌクレオチド、2’−アルキル−修飾ヌクレオチド、モルホリノヌクレオチド、ホスホルアミデート、およびヌクレオチドを含む非天然塩基から成る群から選択される、請求項3に記載のFLiP。
- 前記相補性領域が、19から21ヌクレオチドの長さの間である、請求項2に記載のFLiP。
- 前記dsRNAが、前記dsRNAの片方または両方の末端に1本鎖オーバーハングを含む、請求項2に記載のFLiP。
- 前記センス鎖およびアンチセンス鎖の各々が、19個の塩基対相補性を有する21ヌクレオチドの長さであり、前記dsRNAが、各鎖の3’末端に2ヌクレオチドの1本鎖オーバーハングを有する、請求項2に記載のFLiP。
- 前記脂溶性物質抱合体が、コレステロール部分である、請求項1に記載のFLiP。
- 2本の鎖を含む2本鎖オリゴヌクレオチドを哺乳類の組織にイン・ビトロで選択的に標的化または送達するための方法であって、前記組織を請求項1記載のFLiPに接触させることを含む方法。
- 前記哺乳類の組織が、心臓組織、肺組織、および/または筋肉組織である、請求項10に記載の方法。
- 各鎖が、19個の塩基対相補性を有する21ヌクレオチドの長さであり、各鎖が、3’末端に2ヌクレオチドの1本鎖オーバーハングを有する、請求項10に記載の方法。
- 前記2本鎖オリゴヌクレオチドが、コレステロール部分で修飾される、請求項12に記載の方法。
- 前記2本鎖オリゴヌクレオチドが、ApoBまたはRhoAを標的とする、請求項10に記載の方法。
- 哺乳類の組織を請求項1または2または8に記載のFLiPに接触させることを含む、哺乳類の組織における遺伝子の発現をイン・ビトロで低減させる方法。
- 前記哺乳類の組織が、心臓組織、肺組織、および/または筋肉組織である、請求項15に記載の方法。
- 請求項1記載のFLiPを含む、2本の鎖を含む2本鎖オリゴヌクレオチドを哺乳類の組織に選択的に標的化または送達するための医薬組成物。
- 前記哺乳類の組織が、心臓組織、肺組織、および/または筋肉組織である、請求項17に記載の医薬組成物。
- 各鎖が、19個の塩基対相補性を有する21ヌクレオチドの長さであり、各鎖が、3’末端に2ヌクレオチドの1本鎖オーバーハングを有する、請求項17に記載の医薬組成物。
- 前記2本鎖オリゴヌクレオチドが、コレステロール部分で修飾される、請求項19に記載の医薬組成物。
- 前記2本鎖オリゴヌクレオチドが、ApoBまたはRhoAを標的とする、請求項17に記載の医薬組成物。
- 請求項1に記載のFLiPを含む、哺乳動物の組織における遺伝子の発現を低減させるための医薬組成物。
- 前記哺乳類の組織が、心臓組織、肺組織、および/または筋肉組織である、請求項22に記載の医薬組成物。
- 前記組織における遺伝子の発現が哺乳類においてインビボで低減され、哺乳類への全身送達を介して前記組織と接触されるためのものである、請求項22に記載の医薬組成物。
- 請求項1または2または8に記載のFLiPを含む凍結乾燥物。
- 前記オリゴヌクレオチドがApoBまたはRhoAを標的とする、請求項1または2または8に記載のFLiP。
- 前記20%静脈内脂肪エマルションがトリグリセロール、リン脂質、グリセロール、および1つまたは複数の脂質結合タンパク質を含む、請求項1または2または8に記載のFLiP。
- 前記20%静脈内脂肪エマルションが20%のトリアシルグリセロール、1.2%のリン脂質、2.25%のグリセロールおよび1つまたは複数の脂質結合タンパク質を含む、請求項27に記載のFLiP。
- 前記20%静脈内脂肪エマルションが20%の大豆油、1.2%の卵黄リン脂質、2.25%のグリセリン、および水を含む、請求項27に記載のFLiP。
- 20〜50nm の粒子サイズを有する、請求項1または2または8に記載のFLiP。
- 35nmの粒子サイズを有する、請求項1または2または8に記載のFLiP。
- 前記脂溶性物質抱合体がコレステロールを含み、前記20%静脈内脂肪エマルションが20%の大豆油、1.2%の卵黄リン脂質、2.25%のグリセリン、および水を含み、粒子サイズが35nmである、請求項1または2または8に記載のFLiP。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08005800A EP2105145A1 (en) | 2008-03-27 | 2008-03-27 | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
EP08005800.1 | 2008-03-27 | ||
US4038608P | 2008-03-28 | 2008-03-28 | |
US61/040,386 | 2008-03-28 | ||
PCT/US2009/038437 WO2009120887A2 (en) | 2008-03-27 | 2009-03-26 | Compositions and methods for mediating rnai in vivo |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011517676A JP2011517676A (ja) | 2011-06-16 |
JP2011517676A5 true JP2011517676A5 (ja) | 2012-05-17 |
Family
ID=39683892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502065A Pending JP2011517676A (ja) | 2008-03-27 | 2009-03-26 | インビボでrna干渉を媒介するための組成物および方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8148344B2 (ja) |
EP (2) | EP2105145A1 (ja) |
JP (1) | JP2011517676A (ja) |
WO (1) | WO2009120887A2 (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008317566B2 (en) | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
CN101951924B (zh) | 2007-11-09 | 2015-06-24 | 得克萨斯系统大学董事会 | Mir-15家族的微小rna调控心肌细胞存活和心脏修复 |
CA2718520C (en) | 2008-03-17 | 2020-01-07 | The Board Of Regents Of The University Of Texas System | Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration |
EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
AU2011207563B2 (en) | 2010-01-19 | 2016-03-10 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
AU2013212758A1 (en) | 2012-01-27 | 2014-08-14 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy |
JP2013256452A (ja) * | 2012-06-11 | 2013-12-26 | Kawaken Fine Chem Co Ltd | メラニン産生抑制剤とその組成物 |
US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
ES2750608T3 (es) | 2013-07-25 | 2020-03-26 | Exicure Inc | Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico |
WO2015023797A1 (en) | 2013-08-13 | 2015-02-19 | Northwestern University | Lipophilic nanoparticles for drug delivery |
JP6621409B2 (ja) | 2013-11-22 | 2019-12-18 | ミナ セラピューティクス リミテッド | C/EBPα小分子活性化RNA組成物 |
CN112107693B (zh) * | 2013-12-03 | 2023-05-26 | 西北大学 | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 |
WO2015161184A1 (en) | 2014-04-18 | 2015-10-22 | University Of Massachusetts | Exosomal loading using hydrophobically modified oligonucleotides |
ES2725948T3 (es) | 2014-06-04 | 2019-09-30 | Exicure Inc | Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas |
EP3204499A4 (en) | 2014-10-06 | 2018-04-25 | Exicure, Inc. | Anti-tnf compounds |
CN107106493A (zh) | 2014-11-21 | 2017-08-29 | 西北大学 | 球形核酸纳米颗粒缀合物的序列特异性细胞摄取 |
CN108064295A (zh) | 2015-01-14 | 2018-05-22 | 埃克西奎雷股份有限公司 | 具有核心基序的核酸纳米结构 |
WO2017062699A1 (en) * | 2015-10-07 | 2017-04-13 | Cormedix Inc. | Skin-penetrating formulation of taurolidine |
US10967072B2 (en) | 2016-04-27 | 2021-04-06 | Northwestern University | Short interfering RNA templated lipoprotein particles (siRNA-TLP) |
AU2017261360A1 (en) | 2016-05-06 | 2018-11-29 | Exicure Operating Company | Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
WO2018152327A1 (en) * | 2017-02-15 | 2018-08-23 | Northwestern University | Enhancing stability and immunomodulatory activity of liposomal spherical nucleic acids |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
MX2020000387A (es) | 2017-07-13 | 2020-08-17 | Univ Northwestern | Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos. |
WO2019048632A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE |
US20200208152A1 (en) | 2017-09-08 | 2020-07-02 | Mina Therapeutics Limited | Stabilized sarna compositions and methods of use |
EP4242307A3 (en) | 2018-04-12 | 2023-12-27 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
EP3953473A1 (en) | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
JP7463410B2 (ja) * | 2019-07-02 | 2024-04-08 | アルゴノート アールエヌエー リミテッド | アポリポタンパク質bアンタゴニスト |
GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
AU2022246144A1 (en) | 2021-03-26 | 2023-09-21 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
WO2024134199A1 (en) | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4426330A (en) * | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4534899A (en) * | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
JPS5927900A (ja) * | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
FR2540122B1 (fr) * | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4605735A (en) * | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) * | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4824941A (en) * | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4587044A (en) * | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US5118802A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5430136A (en) * | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US5258506A (en) * | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US4828979A (en) * | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
US4762779A (en) * | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
JPS638396A (ja) * | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
US4904582A (en) * | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5585481A (en) * | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5525465A (en) * | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (de) * | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
US5082830A (en) * | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
US5109124A (en) * | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5262536A (en) * | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
US5512439A (en) * | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5457183A (en) * | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5599923A (en) * | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
JPH04503957A (ja) * | 1989-03-07 | 1992-07-16 | ジェネンテク,インコーポレイテッド | 脂質とオリゴヌクレオチドの共有結合コンジュゲート |
US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5032401A (en) * | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US5451463A (en) * | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5254469A (en) * | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5292873A (en) * | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5486603A (en) * | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5214136A (en) * | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
AU7579991A (en) * | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
EP0455905B1 (en) * | 1990-05-11 | 1998-06-17 | Microprobe Corporation | Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides |
US5218105A (en) * | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5608046A (en) * | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5688941A (en) * | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5138045A (en) * | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5245022A (en) * | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5512667A (en) * | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
KR930702373A (ko) * | 1990-11-08 | 1993-09-08 | 안토니 제이. 페이네 | 합성 올리고누클레오티드에 대한 다중 리포터(Reporter)그룹의 첨합 |
US5371241A (en) * | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
US5595726A (en) * | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
US5565552A (en) * | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
US5272250A (en) * | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5217098A (en) * | 1992-10-19 | 1993-06-08 | Adams Rite Manufacturing Company | Apparatus for integrating transmission control and brake control |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
JP3351476B2 (ja) * | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
CA2137297C (en) * | 1993-12-06 | 2000-04-18 | Tsuyoshi Miyazaki | Reactive vesicle and functional substance-fixed vesicle |
US5597696A (en) * | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
US5580731A (en) * | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
DE69834038D1 (de) * | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
AU745880B2 (en) * | 1998-05-21 | 2002-04-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
JP2002537343A (ja) | 1999-02-23 | 2002-11-05 | アイシス・ファーマシューティカルス・インコーポレーテッド | 多重粒子製剤 |
GB9930533D0 (en) * | 1999-12-23 | 2000-02-16 | Mitsubishi Tokyo Pharm Inc | Nucleic acid delivery |
CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
WO2002087594A1 (en) * | 2001-04-30 | 2002-11-07 | The Regents Of The University Of California | Non-viral vesicle vector for cardiac specific gene delivery |
US20050277133A1 (en) * | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
GB0118517D0 (en) * | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
US7956176B2 (en) * | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
DE10302421A1 (de) | 2003-01-21 | 2004-07-29 | Ribopharma Ag | Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit |
WO2005118612A1 (en) * | 2004-06-04 | 2005-12-15 | Sonus Pharmaceuticals, Inc. | Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs |
US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
FR2894582B1 (fr) * | 2005-12-12 | 2008-02-22 | Fabre Pierre Dermo Cosmetique | Sirna anti myosine va et depigmentation de la peau |
US20100004320A1 (en) | 2006-04-03 | 2010-01-07 | Santaris Pharma A/S | Pharmaceutical Composition |
EP1844772A1 (en) * | 2006-04-06 | 2007-10-17 | Polyplus-Transfection SA | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
-
2008
- 2008-03-27 EP EP08005800A patent/EP2105145A1/en not_active Withdrawn
-
2009
- 2009-03-26 WO PCT/US2009/038437 patent/WO2009120887A2/en active Application Filing
- 2009-03-26 EP EP09724197A patent/EP2265289A2/en not_active Withdrawn
- 2009-03-26 JP JP2011502065A patent/JP2011517676A/ja active Pending
- 2009-03-26 US US12/412,206 patent/US8148344B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011517676A5 (ja) | ||
AU2020257111B2 (en) | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy | |
JP6553001B2 (ja) | 皮膚および線維症適用におけるrna干渉 | |
Yu et al. | Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination | |
JP2023052363A5 (ja) | ||
US9957504B2 (en) | Compositions and methods for modulating apolipoprotein (a) expression | |
JP6208228B2 (ja) | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 | |
JP5244087B2 (ja) | 低分子内部セグメント化干渉rna | |
CN102803284B (zh) | 用于miRNA抑制剂和模拟物的化学修饰基序 | |
AU2012353058B2 (en) | Novel oligonucleotide conjugates and use thereof | |
JP2018512155A5 (ja) | ||
ES2537568T3 (es) | Nuevos fármacos para inhibición de la expresión genética | |
JP2020033350A (ja) | 化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法 | |
JP2009513144A5 (ja) | ||
EP2805713B1 (en) | Magnetic nanoparticle-samirna complex and method for preparing same | |
EP2105145A1 (en) | Method for muscle-specific delivery lipid-conjugated oligonucleotides | |
Shah et al. | Small non-coding RNA therapeutics for cardiovascular disease | |
CN103003430A (zh) | 反义分子和治疗疾病的方法 | |
BR112014016562B1 (pt) | Estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação | |
JP2011518117A5 (ja) | ||
JP2014527401A5 (ja) | ||
JP2010537640A (ja) | マイクロrna模倣剤または阻害剤としての非対称性rna二重鎖の組成物 | |
JP2023539341A (ja) | Dux4阻害剤およびその使用方法 | |
EP2565278A1 (en) | Method for the delivery of oligonucleotides | |
JP2019527549A (ja) | 転写プロセシングの調節のための化合物及び方法 |